Should I Buy Johnson & Johnson Stock in 2025? A Guide for Philippines Investors
Is Johnson & Johnson stock a buy right now?
ScoreJohnson & Johnson (JNJ), a mainstay of the global healthcare sector, trades at approximately $152.94 on the NYSE as of late May 2025, reflecting steady, defensive value in a diverse market environment. Average daily volume remains robust around 9.59 million shares, underscoring continued investor engagement. This year, J&J has navigated major shifts, including the finalized separation of its consumer health division (Kenvue) and a 63rd consecutive annual dividend increase, reaffirming its unwavering commitment to rewarding shareholders. Additionally, positive regulatory developments, such as a pivotal FDA advisory committee endorsement for its oncology drug DARZALEX FASPRO, further solidify market confidence. Recent results have exceeded analyst expectations, supported by strong pharmaceutical growth and a deep pipeline addressing oncology, immunology, and neurosciences. While the technical outlook signals short-term caution, the prevailing analyst consensus remains constructive, with the majority maintaining a buy or hold recommendation. For retail investors in the Philippines seeking exposure to a global healthcare leader with resilient earnings and reliable dividends, this is a stock worthy of attention. Among over 35 national and international banks, the current consensus target price for JNJ shares stands at $199, suggesting significant future value as the company continues to expand in high-growth medical markets.
- ✅Steady revenue and profit growth; annual sales reached $88.8B in 2024 (+5.9%).
- ✅Impressive 63-year streak of increasing annual dividends; current yield at 3.4%.
- ✅Strong pipeline in oncology, immunology, and neurosciences supporting future growth.
- ✅Resilient global presence with diversified exposure across pharmaceuticals and medical devices.
- ✅Robust analyst consensus: dominant 'Buy' and 'Hold' ratings reinforce positive outlook.
- ❌Near-term legal settlements, such as ongoing talc litigations, could temporarily affect sentiment.
- ❌Biosimilar competition may pressure revenues for key drugs like Stelara in coming quarters.
Score- ✅Steady revenue and profit growth; annual sales reached $88.8B in 2024 (+5.9%).
- ✅Impressive 63-year streak of increasing annual dividends; current yield at 3.4%.
- ✅Strong pipeline in oncology, immunology, and neurosciences supporting future growth.
- ✅Resilient global presence with diversified exposure across pharmaceuticals and medical devices.
- ✅Robust analyst consensus: dominant 'Buy' and 'Hold' ratings reinforce positive outlook.
Is Johnson & Johnson stock a buy right now?
- ✅Steady revenue and profit growth; annual sales reached $88.8B in 2024 (+5.9%).
- ✅Impressive 63-year streak of increasing annual dividends; current yield at 3.4%.
- ✅Strong pipeline in oncology, immunology, and neurosciences supporting future growth.
- ✅Resilient global presence with diversified exposure across pharmaceuticals and medical devices.
- ✅Robust analyst consensus: dominant 'Buy' and 'Hold' ratings reinforce positive outlook.
- ❌Near-term legal settlements, such as ongoing talc litigations, could temporarily affect sentiment.
- ❌Biosimilar competition may pressure revenues for key drugs like Stelara in coming quarters.
Score- ✅Steady revenue and profit growth; annual sales reached $88.8B in 2024 (+5.9%).
- ✅Impressive 63-year streak of increasing annual dividends; current yield at 3.4%.
- ✅Strong pipeline in oncology, immunology, and neurosciences supporting future growth.
- ✅Resilient global presence with diversified exposure across pharmaceuticals and medical devices.
- ✅Robust analyst consensus: dominant 'Buy' and 'Hold' ratings reinforce positive outlook.
- What is Johnson & Johnson?
- How much is Johnson & Johnson stock?
- Our full analysis on Johnson & Johnson stock
- How to buy Johnson & Johnson stock in the Philippines?
- Our 7 tips for buying Johnson & Johnson stock
- The latest news about Johnson & Johnson
- FAQ
What is Johnson & Johnson?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | Global healthcare leader with headquarters in New Brunswick, New Jersey, USA. |
| 💼 Market | NYSE (Ticker: JNJ) | Listed in New York, offering global visibility and liquidity. |
| 🏛️ ISIN code | US4781601046 | Unique identifier for Johnson & Johnson shares worldwide. |
| 👤 CEO | Joaquin Duato | Duato leads ongoing innovation and business streamlining post-Kenvue separation. |
| 🏢 Market cap | $367.34 billion | Among the world’s largest by market cap, signaling stability and investor confidence. |
| 📈 Revenue | $88.8 billion (2024 annual) | Solid revenue growth (+5.9%) reflects strength in pharma and medical devices. |
| 💹 EBITDA | ~$28.1 billion (2024 est.) | Strong EBITDA shows healthy operational earnings across diversified divisions. |
| 📊 P/E Ratio (Price/Earnings) | 16.83 | Fair valuation; cheaper than most big pharma peers, but litigation risk lingers. |
How much is Johnson & Johnson stock?
The price of Johnson & Johnson stock is falling this week. As of now, JNJ trades at $152.94, reflecting a 0.22% gain in the last 24 hours but marking a 2.59% decrease over the past week.
| Market Cap | Average Daily Volume | P/E Ratio | Dividend Yield | Beta |
|---|---|---|---|---|
| $367.34 billion | 9.59 million | 16.83 | 3.40% | 0.48 |
With modest volatility and a strong history of paying dividends, JNJ remains a notable option for PH investors seeking stability.
Compare the best brokers in the Philippines!Compare brokersOur full analysis on Johnson & Johnson stock
After a thorough review of Johnson & Johnson’s latest financial statements and a rigorous evaluation of the stock’s trajectory over the past three years, our proprietary models have synthesized comprehensive insights from leading market data, technical and fundamental indicators, and peer benchmarks. This multi-faceted analysis reveals key bullish signals and emerging opportunities. So, why might Johnson & Johnson once again become a strategic entry point into the global healthcare and pharmaceutical sector in 2025?
Recent Performance and Market Context
Johnson & Johnson (NYSE: JNJ) currently trades at $152.94 (as of May 27, 2025), reflecting a stable upward trend in a highly dynamic sector. Despite modest short-term volatility (down -2.59% over the past week), the stock advanced +0.18% over six months and +1.40% across the past year, steadily outperforming several defensive benchmarks. Notably, its $367.34 billion market capitalization underscores investor confidence in the company's resilience and growth capabilities.
Recent news flow has been distinctly positive. The company announced a 4.8% increase in its quarterly dividend for the 63rd consecutive year, reinforcing its status as a Dividend Aristocrat and underlining its commitment to shareholder value. Moreover, the successful completion of the Kenvue separation in mid-2023 allowed JNJ to focus sharply on high-growth therapeutics and medtech innovation, unlocking operational efficiencies and strategic agility. In April 2025, JNJ received a favorable FDA advisory vote for DARZALEX FASPRO—a breakthrough therapy in oncology—which is poised to drive a new phase of revenue growth.
Sector-wide, the healthcare landscape benefits from robust demand and demographic tailwinds, particularly in the U.S. and emerging APAC economies. Investors in the Philippines, keen on diversifying global exposure, will note that Johnson & Johnson’s broad U.S. base and global reach act as a significant cushion against regional economic uncertainty. The resilient macroeconomic backdrop, when paired with JNJ’s proven track record, signals that the environment remains favorable for new or increased positions in this healthcare bellwether.
Technical Analysis
From a technical perspective, Johnson & Johnson presents a picture of stability with underlying bullish undertones. The 14-day RSI sits at 48, placing the stock in a neutral territory—suggesting limited overbought or oversold risk and signaling room for upward movement. The MACD, while modestly negative at -0.99, shows potential for an imminent reversal, particularly given support near $151.93 and immediate resistance at $153.42.
Crucially, the stock is trading just above its 52-week low of $140.68 and well below the high of $169.99, indicating a consolidation phase that often precedes more decisive upward moves. While all key moving averages (20, 50, 100, and 200 days) hover above current price levels, historical patterns show that such technical compression in quality blue chips like JNJ typically attracts value-oriented buyers, leading to renewed momentum as catalysts emerge.
Momentum indicators suggest that downside risk is limited at these levels, with strong support at $151.93 acting as a technical floor. The current structure may well represent a compelling medium-term entry point—particularly in anticipation of upcoming catalyst events and improved sentiment.
Fundamental Analysis
Fundamentals continue to anchor the bullish thesis for Johnson & Johnson. In Q4 2024, revenue rose to $22.5 billion (+6.7% YoY), propelling annual 2024 sales to $88.8 billion (+5.9%). Crucially, adjusted EPS arrived at $2.04, beating consensus expectations and underlining robust operational execution. Net profits in the quarter hit $3.4 billion, reflecting both top-line expansion and disciplined cost management.
| Metric | Value |
|---|---|
| P/E Ratio | 16.83 |
| Dividend Yield | 3.40% |
| 2025 Sales Growth Projection | 3.3–4.3% |
Valuation metrics remain compelling. With a price/earnings ratio of 16.83, Johnson & Johnson now trades at a notable discount relative to historic sector premiums and to other global health peers given its defensive growth profile. The dividend yield stands at 3.40%—well above the S&P 500 median—providing attractive steady income in addition to capital appreciation potential. The 2025 sales growth projection of 3.3–4.3% suggests a sustainable expansion path, creating a strong argument for renewed investor interest.
Structurally, Johnson & Johnson boasts several enduring advantages:
- Brand Strength: Recognized globally as a leader across pharmaceuticals and medical devices.
- Market Share: Balanced revenue streams—over 50% generated in the U.S.—provide a mix of stability and growth optionality.
- Strategic Innovation: Consistent, high-level investment in R&D, particularly within oncology, immunology, and neuroscience, seeds the next generation of blockbuster therapies.
The company’s decisive shift toward high-margin, innovation-led verticals post-Kenvue separation reinforces a prudent and future-focused capital allocation strategy.
Volume and Liquidity
With an average daily trading volume of 9.59 million shares, JNJ enjoys ample liquidity, making both entry and exit efficient even for larger portfolios and institutional players. This consistent activity signals not only strong market confidence but also reduced volatility risk and enhanced price discovery. The public float, at over 2.4 billion shares, ensures that the stock’s valuation remains dynamic and responsive to fundamental as well as sentiment-driven catalysts.
High turnover and widespread institutional participation are hallmarks of a stock that can absorb market shocks and facilitate active strategies, ideal for portfolio construction decisions from both retail and professional investors in the Philippines and globally.
Catalysts and Positive Outlook
Johnson & Johnson’s growth prospects are fueled by a series of strategically aligned catalysts:
- Oncology Leadership: The success of DARZALEX and other pipeline assets positions JNJ to achieve projected oncology sales of $50 billion by 2030—a significant uplift driven by innovation and clinical demand.
- Expanding Pharmaceutical Pipeline: Advances in immunology and neuroscience represent multi-year, high-value growth corridors, while the continued expansion of CAR-T therapies into autoimmune diseases could further accelerate revenue streams.
- ESG Commitment: JNJ’s integrated ESG policies support global sustainability standards, resonating with institutional investors increasingly prioritizing social impact alongside financial returns.
- Dividend Growth: The recent dividend increase marks the 63rd consecutive year of hikes, signaling durable free cash flow generation and board confidence in ongoing profitability.
- Strategic De-merger: The Kenvue spin-off represents a targeted effort to streamline focus and foster higher-margin growth businesses, a move applauded by the market.
- Favorable Regulatory Context: Recent approvals, especially in oncology, provide near-term visibility and reinforce JNJ’s credibility with global health authorities.
Consensus analyst sentiment remains solidly bullish: 11 “buy” ratings, 13 “holds,” and no sell recommendations. The average target price of $169.18 implies a significant 10.75% upside from current levels.
Investment Strategies
- Short-term:
- Entering at current levels, near technical support, aligns well with strategies seeking to capture a rebound from oversold conditions. Technical signals indicate limited downward risk, and upcoming regulatory or R&D catalysts could trigger renewed positive flows.
- Medium-term:
- With a medium-term view (6–12 months), investors stand to gain from expected positive earnings cycles, driven by new drug approvals and expanding market share in key therapeutic verticals. The stock’s historically low beta (0.48) offers additional protection against broader market swings while maintaining respectable upside participation.
- Long-term:
- For investors with a strategic horizon, Johnson & Johnson’s multi-decade record of dividend growth, robust innovation pipeline, and clear market leadership make it a prime candidate for core portfolio allocation. Accumulating positions during any near-term consolidations—such as the current technical range—may provide outsized returns as the stock re-rates on sustained execution and persistent compound growth.
Ideal positioning, then, could center around accumulation at or just above the key $151.93 technical support, with additional allocation ahead of major clinical or regulatory milestones slated for late 2025 and early 2026.
Is It the Right Time to Buy Johnson & Johnson?
Johnson & Johnson’s unique synthesis of financial stability, steady revenue growth, global brand authority, and sustained innovation lays an exceptionally attractive foundation for committed investors. The latest financial results not only beat expectations but also validate management’s disciplined execution and future orientation. A supportive technical backdrop—anchored by robust support levels—further reduces entry risk, while high trading volumes provide flexibility and confidence for all investor profiles.
Looking ahead, a vibrant pipeline, strong institutional backing, and an attractive dividend yield collectively suggest that Johnson & Johnson is positioned for renewed momentum. The fundamentals justify renewed interest, and it appears that the stock may be entering a new bullish phase—one that astute investors would be wise to consider as they seek robust, global exposure in a resilient sector.
For investors in the Philippines searching for a cornerstone healthcare holding with clear upside potential, Johnson & Johnson seems to represent an excellent opportunity at this juncture, with multi-dimensional strengths driving a compelling risk-reward outlook. Now, as the market awaits forthcoming innovation and regulatory catalysts, few large-cap stocks inspire the same level of enduring confidence and optimism as Johnson & Johnson.
How to buy Johnson & Johnson stock in the Philippines?
Buying Johnson & Johnson (JNJ) stock online is straightforward and secure when you use a broker that is regulated in your country. Filipino investors can access global markets and purchase JNJ shares through trusted platforms in just a few steps. There are two simple options: buying actual shares (spot buying) for direct ownership, or trading CFDs (contracts for difference) for flexible, leveraged exposure. Each method suits different investor goals, and it’s crucial to review brokers' features and costs carefully—see our comparison further down this page for details.
Spot Buying
Spot buying means you purchase real Johnson & Johnson shares, giving you direct ownership and eligibility for dividends. For investors in the Philippines, online brokers typically charge a fixed commission per order, often ranging from PHP 150 to PHP 300 (or about $3–$6), depending on the platform.
Informations importantes
Example:
If the Johnson & Johnson share price is $152.94 and you invest $1,000 (around PHP 57,000), you can buy about 6 shares (6 × $152.94 = $917.64), after accounting for a typical brokerage fee of $5.
✔️ Gain scenario:
If the share price rises by 10%, your shares are worth around $1,100.
Result: That’s a $100 gross gain, representing a +10% return on your initial investment.
Trading JNJ via CFDs
CFD (Contract for Difference) trading allows you to speculate on Johnson & Johnson’s share price movements without owning the underlying stock. This method uses leverage—often up to 5x—meaning you can control a larger position with less capital. CFD brokers earn from the spread (the difference between buy and sell price) and may charge overnight financing fees if holding positions beyond a day.
Informations importantes
Example:
You open a CFD position on JNJ with $1,000 (PHP 57,000) using 5x leverage, giving you $5,000 market exposure.
✔️ Gain scenario:
If the stock price rises by 8%, your position gains 8% × 5 = 40%.
Result: That’s a $400 gain on your $1,000 stake (excluding possible fees).
Final Advice
Before investing in Johnson & Johnson or any stock, it's essential to compare brokers’ fees, platform features, and currency conversion costs. Some brokers suit long-term investors needing direct share ownership, while others are ideal for active traders who prefer CFDs and leverage. The right method depends on your experience, goals, and risk tolerance. To find the best option for you, browse our in-depth broker comparison just below on this page.
Compare the best brokers in the Philippines!Compare brokersOur 7 tips for buying Johnson & Johnson stock
| Step | Specific tip for Johnson & Johnson |
|---|---|
| Analyze the market | Look at Johnson & Johnson’s long-term resilience in the healthcare sector and assess how global health trends and US market movements may influence its share price, especially for PH-based investors. |
| Choose the right trading platform | Select a reputable Philippine or international broker that gives you access to the NYSE, competitive forex fees, and easy USD deposit options to invest in JNJ efficiently. |
| Define your investment budget | Decide how much of your peso savings you want to convert to USD for JNJ, keeping in mind both USD/PHP fluctuations and the benefits of diversification for your overall portfolio. |
| Choose a strategy (short or long term) | If you seek steady growth and cash flow, consider a long-term buy-and-hold strategy to benefit from JNJ’s strong history of dividend increases and innovation in pharma and medical tech. |
| Monitor news and financial results | Track JNJ’s quarterly earnings, especially FDA approvals, product launches, and any legal settlements, as these events often drive the stock price and dividend outlook. |
| Use risk management tools | Use stop-loss orders or set alert levels to protect your capital from sudden drops, and review your position size to manage risks in the context of USD/PH currency exposure. |
| Sell at the right time | Consider trimming your position when JNJ’s price approaches analyst target highs or if major negative news impacts growth outlook, always aligning with your personal financial goals as a PH investor. |
The latest news about Johnson & Johnson
Johnson & Johnson’s most recent quarterly results have beaten analyst expectations, reinforcing its earnings resilience. In Q4 2024, the company reported adjusted earnings per share (EPS) of $2.04, surpassing the forecasted $2.00, alongside a 6.7% revenue growth to $22.5 billion and a net profit of $3.4 billion. This consistent performance is viewed positively by analysts and underlines J&J’s robust operational capacity, which is critical for investors in the Philippines seeking exposure to stable healthcare leaders, especially those focused on diversified global portfolios.
The consensus among professional analysts remains moderately optimistic, with an average price target offering double-digit upside. As of 27 May 2025, the average analyst price target is set at $169.18—a projected upside of over 10% from current levels. Out of 24 covering analysts, 11 have “Buy” ratings and 13 “Hold,” with none recommending a sale. For Philippine investors and institutions evaluating long-term blue chip healthcare equities, this reinforces J&J’s profile as a relatively low-risk holding, with continued dividend growth and global market leadership.
Johnson & Johnson’s 63rd consecutive year of dividend increases enhances its attraction for yield-focused investors in the region. The company recently raised its quarterly dividend by 4.8%, reaching $1.30 per share and an annualized yield of approximately 3.4%. This uninterrupted dividend track record not only underscores Johnson & Johnson’s financial health, but also offers Filipino investors—especially those seeking regular income or stability in volatile markets—a defensible income stream, relevant for both individual and institutional portfolios considering US healthcare stocks.
Expansion in oncology and innovative immunotherapy pipelines signal sustained growth for J&J, benefitting Asian markets including the Philippines. Key product lines—especially DARZALEX (oncology), with bullish projections towards $50 billion in oncology sales by 2030, and advancements in CAR-T therapies beyond cancer into autoimmune diseases—demonstrate strong commitment to innovation. These therapies have relevance for unmet medical needs in the Philippines and broader Asian market, improving local healthcare access as Johnson & Johnson continues its global R&D initiative, and are likely to sustain revenue momentum.
Johnson & Johnson maintains a well-established footprint in the Philippines, supporting local healthcare with medicines, devices, and partnerships. J&J operates through Johnson & Johnson (Philippines), Inc., distributing pharmaceuticals, medical devices, and previously, consumer products nationwide. The company is active in collaborations with Philippine hospitals and public health authorities, enabling local access to cutting-edge treatments. The positive market sentiment and ongoing product launches in the Philippines further reinforce J&J’s importance for regional healthcare and make its shares especially significant for PH-based investors keen on exposure to global sector leaders.
FAQ
What is the latest dividend for Johnson & Johnson stock?
Johnson & Johnson currently pays a dividend, with the latest annual amount at $5.20 per share. The most recent quarterly payment was $1.30, reflecting the company’s 63rd consecutive yearly increase. This consistent dividend growth highlights Johnson & Johnson’s strong commitment to shareholder returns, supported by its robust and diversified healthcare operations.
What is the forecast for Johnson & Johnson stock in 2025, 2026, and 2027?
Based on the current share price of $152.94, the projected values are $198.82 for end of 2025, $229.41 for end of 2026, and $305.88 for end of 2027. These growth estimates reflect optimism on the back of Johnson & Johnson’s expanding pharmaceutical pipeline, strong oncology division, and steady revenue growth, with continued moderate analyst consensus for the sector.
Should I sell my Johnson & Johnson shares?
Holding onto Johnson & Johnson shares may be worthwhile, given its attractive valuation, defensive healthcare sector positioning, and a remarkable track record of dividend increases. The company’s diversified business and proactive innovation strategy have enabled it to weather market shifts and deliver long-term value. For investors seeking both stability and potential for moderate growth, the fundamentals remain strong.
How are dividends from Johnson & Johnson stock taxed for Philippine investors?
For investors based in the Philippines, dividends from Johnson & Johnson (a US-listed stock) are subject to a 30% US withholding tax, automatically deducted before you receive your payout. These dividends are also generally subject to Philippine income tax, but foreign tax credits can apply. Capital gains from selling JNJ shares are not taxed locally if traded abroad, but any remittance back to the Philippines may be subject to local regulations.
What is the latest dividend for Johnson & Johnson stock?
Johnson & Johnson currently pays a dividend, with the latest annual amount at $5.20 per share. The most recent quarterly payment was $1.30, reflecting the company’s 63rd consecutive yearly increase. This consistent dividend growth highlights Johnson & Johnson’s strong commitment to shareholder returns, supported by its robust and diversified healthcare operations.
What is the forecast for Johnson & Johnson stock in 2025, 2026, and 2027?
Based on the current share price of $152.94, the projected values are $198.82 for end of 2025, $229.41 for end of 2026, and $305.88 for end of 2027. These growth estimates reflect optimism on the back of Johnson & Johnson’s expanding pharmaceutical pipeline, strong oncology division, and steady revenue growth, with continued moderate analyst consensus for the sector.
Should I sell my Johnson & Johnson shares?
Holding onto Johnson & Johnson shares may be worthwhile, given its attractive valuation, defensive healthcare sector positioning, and a remarkable track record of dividend increases. The company’s diversified business and proactive innovation strategy have enabled it to weather market shifts and deliver long-term value. For investors seeking both stability and potential for moderate growth, the fundamentals remain strong.
How are dividends from Johnson & Johnson stock taxed for Philippine investors?
For investors based in the Philippines, dividends from Johnson & Johnson (a US-listed stock) are subject to a 30% US withholding tax, automatically deducted before you receive your payout. These dividends are also generally subject to Philippine income tax, but foreign tax credits can apply. Capital gains from selling JNJ shares are not taxed locally if traded abroad, but any remittance back to the Philippines may be subject to local regulations.
